Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections

被引:87
作者
Hermsen, Elizabeth D. [1 ,2 ,5 ]
Hanson, Monica [1 ]
Sankaranarayanan, Jayashri [2 ]
Stoner, Julie A. [3 ]
Florescu, Marius C. [4 ]
Rupp, Mark E. [5 ]
机构
[1] Univ Nebraska Med Ctr, Dept Pharmaceut & Nutr Care, Omaha, NE 68918 USA
[2] Univ Nebraska Med Ctr, Coll Pharm, Dept Pharm Practice, Omaha, NE 68918 USA
[3] Univ Oklahoma, Coll Publ Hlth, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK USA
[4] Univ Nebraska Med Ctr, Coll Med, Nephrol Sect, Dept Internal Med, Omaha, NE 68918 USA
[5] Univ Nebraska Med Ctr, Coll Med, Infect Dis Sect, Dept Internal Med, Omaha, NE 68918 USA
关键词
outcome assessment; therapeutic drug monitoring; toxicity; vancomycin; STAPHYLOCOCCUS-AUREUS; EFFICACY;
D O I
10.1517/14740330903413514
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Higher vancomycin concentrations are thought necessary for treatment of deep-seated methicillin-resistant Staphylococcus aureus (MRSA) infection, yet this may result in greater risk of nephrotoxicity. We evaluated the relationship of serum vancomycin trough concentration with clinical outcomes and nephrotoxicity for patients with deep-seated MRSA infection. Methods: A retrospective cohort study evaluated adults with MRSA pneumonia, endocarditis or osteomyelitis who received vancomycin for 5 days from June 2005 to June 2007. Patients were stratified by mean vancomycin trough level [low (< 15 mg/l), high (>= 15 mg/l)]. Outcomes were clinical response, mortality, length of stay (LOS) and nephrotoxicity. Three definitions of nephrotoxicity were used: i) rise in serum creatinine (SCr) >= 0.5 mg/dl; ii) 50% increase in SCr; and iii) 25% decrease in estimated creatinine clearance. Results: Fifty-five patients experiencing MRSA pneumonia (n = 28), endocarditis (n = 9), osteomyelitis (n = 20) and multiple infections (n = 2) were stratified into low (n = 39) and high (n = 16) groups. High group patients were more likely to be septic (p = 0.01) and have a higher APACHE II score (p = 0.01). After adjustment for APACHE II score, clinical response rates among survivors did not differ significantly. Risk of death was not significantly different between the high (19%) and low (5%) group patients (p = 0.1). LOS did not differ significantly between groups (p = 0.7). Nephrotoxicity occurred in the low and high groups, respectively, for 10 and 31% (p = 0.04) with definition 1, 10 and 31% (p = 0.04) with definition 2, and 13 and 25% (p = 0.1) with definition 3. After adjustment for APACHE II score, odds of nephrotoxicity based on definitions 1 or 2 were increased among the high versus low groups (OR = 3.27, 95% Cl: 0.7 15.25, p = 0.1), although not statistically significant. Conclusions: Clinical outcomes did not differ significantly between high and low trough groups for deep-seated MRSA infections. Nephrotoxicity was consistently higher in the high trough group, regardless of the definition used.
引用
收藏
页码:9 / 14
页数:6
相关论文
共 13 条
  • [2] Counterpoint:: Vancomycin and Staphylococcus aureus -: An antibiotic enters obsolescence
    Deresinski, Stan
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 44 (12) : 1543 - 1548
  • [3] High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections -: Efficacy and toxicity
    Hidayat, Levita K.
    Hsu, Donald I.
    Quist, Ryan
    Shriner, Kimberly A.
    Wong-Beringer, Annie
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (19) : 2138 - 2144
  • [4] A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia
    Jeffres, Meghan N.
    Isakow, Warren
    Doherty, Joshua A.
    Micek, Scott T.
    Kollef, Marin H.
    [J]. CLINICAL THERAPEUTICS, 2007, 29 (06) : 1107 - 1115
  • [5] Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia -: Specific evaluation of vancomycin pharmacokinetic indices
    Jeffres, Meghan N.
    Isakow, Warren
    Doherty, Joshua A.
    McKinnon, Peggy S.
    Ritchie, David J.
    Micek, Scott T.
    Kollef, Marin H.
    [J]. CHEST, 2006, 130 (04) : 947 - 955
  • [6] Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin
    Lodise, T. P.
    Graves, J.
    Evans, A.
    Graffunder, E.
    Helmecke, M.
    Lomaestro, B. M.
    Stellrecht, K.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (09) : 3315 - 3320
  • [7] Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity
    Lodise, Thomas P.
    Lomaestro, Ben
    Graves, Jeffrey
    Drusano, G. L.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (04) : 1330 - 1336
  • [8] Relationship between Initial Vancomycin Concentration-Time Profile and Nephrotoxicity among Hospitalized Patients
    Lodise, Thomas P.
    Patel, Nimish
    Lomaestro, Ben M.
    Rodvold, Keith A.
    Drusano, George L.
    [J]. CLINICAL INFECTIOUS DISEASES, 2009, 49 (04) : 507 - 514
  • [9] Rybak Michael, 2009, Am J Health Syst Pharm, V66, P82, DOI [10.2146/ajhp080434, 10.1086/600877]
  • [10] Staphylococcus aureus accessory gene regulator (agr) group II:: Is there a relationship to the development of intermediate-level glycopeptide resistance?
    Sakoulas, G
    Eliopoulos, GM
    Moellering, RC
    Novick, RP
    Venkataraman, L
    Wennersten, C
    DeGirolami, PC
    Schwaber, MJ
    Gold, HS
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (06) : 929 - 938